Kajal Sangal, MD
Ophthalmology · Brighton, MANPI 1386205193
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Alcon at 35.0% of the total. Reporting peaked in 2022 at $843 and has fallen 76.7% since, to $196 in 2025.
Across 45 payments — averaging $54.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$857
- Glaukos Corporation$450
- Amgen$230
- AbbVie$218
- Genentech USA, Inc.$130
- Sight Sciences, Inc.$109
- plus $454 from 9 others
What the payments were for
- Food & beverage$2,34796%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 9 | $857 |
| Glaukos Corporation | 7 | $450 |
| Amgen(2 entities) | 6 | $230 |
| AbbVie(2 entities) | 6 | $218 |
| Genentech USA, Inc. | 1 | $130 |
| Sight Sciences, Inc. | 5 | $109 |
| Rxsight Inc | 1 | $100 |
| Genentech, Inc. | 1 | $88 |
| Alimera Sciences, Inc. | 2 | $63 |
| Dompe US, Inc. | 2 | $58 |
| Ivantis, Inc | 1 | $43 |
| Harrow Eye, LLC | 1 | $34 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| NEW World Medical,inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,447 in reported general payments places this provider in the 70th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 17 | $6,963 |
| BesivanceBesifloxacin Hcl | 26 | $6,206 |
| Lotemax SmLoteprednol Etabonate | 20 | $5,231 |
| Prednisolone Acetate | 26 | $1,916 |
| Latanoprost | 163 | $1,859 |
| Brimonidine Tartrate | 46 | $876 |
| Timolol Maleate | 72 | $774 |
| Dorzolamide Hcl | 33 | $658 |
| ErythromycinErythromycin Base | 13 | $272 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Brighton
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.